News
SLP
18.27
-2.33%
-0.44
SIMULATIONS PLUS INC <SLP.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 1h ago
This PayPal Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Benzinga · 2h ago
Simulations Plus Hosts Virtual Investor Day Showcasing AI-Driven Drug Development Strategy
Reuters · 2h ago
BTIG Downgrades Simulations Plus to Neutral
Benzinga · 3h ago
Simulations Plus downgraded to Neutral from Buy at BTIG
TipRanks · 4h ago
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
Barchart · 8h ago
Simulations Plus Inc. to Report First Quarter Fiscal 2026 Results and Host Earnings Call
Reuters · 1d ago
SIMULATIONS PLUS ANNOUNCES FIRST QUARTER FISCAL YEAR 2026 EARNINGS AND CONFERENCE CALL DATE
Reuters · 1d ago
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
Barchart · 1d ago
Weekly Report: what happened at SLP last week (1208-1212)?
Weekly Report · 3d ago
3 Software Stocks to Watch as the Industry Gains Momentum
NASDAQ · 12/09 13:35
Simulations Plus Responds To FDA Draft Guidance On Streamlined Nonclinical Safety Studies For Monoclonal Antibodies
Benzinga · 12/09 12:57
Simulations Plus: Solid Platform, Soft Outlook (Rating Upgrade)
Seeking Alpha · 12/09 08:31
Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
Barchart · 12/09 06:55
Simulations Plus Updates Executive Compensation Agreements
Reuters · 12/08 21:10
Weekly Report: what happened at SLP last week (1201-1205)?
Weekly Report · 12/08 09:48
Why Shares of Simulations Plus Soared This Week
The Motley Fool · 12/04 17:50
Simulations Plus: Buying On Long-Term Silico Drug-Development
Seeking Alpha · 12/03 02:41
Simulations Plus (SLP) Q3 $67M Net Loss Tests Market’s High-Growth Profitability Narrative
Simply Wall St · 12/03 01:25
More
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.